Clinical trial
A Trial for Patients With Gestational Trophoblastic Disease
NCT00190918 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190918 |
|---|---|
| Title | A Trial for Patients With Gestational Trophoblastic Disease |
| Official title | A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Trophoblastic Neoplasms, Uterine Neoplasms, Hydatidiform Mole, Choriocarcinoma |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 50 |
| Start date | Jul 1, 2006 |
| Completion | Jul 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Aug 9, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: